144 related articles for article (PubMed ID: 35448002)
1. Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report.
Guan Y; Li J; Gong X; Zhu H; Li C; Mei G; Liu X; Pan L; Dai J; Wang Y; Wang E; Liu Y; Wang X
Brain Sci; 2022 Apr; 12(4):. PubMed ID: 35448002
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
She L; Su L; Shen L; Liu C
Front Oncol; 2021; 11():687564. PubMed ID: 34354945
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
Guan Y; Xiong J; Pan M; Shi W; Li J; Zhu H; Gong X; Li C; Mei G; Liu X; Pan L; Dai J; Wang Y; Wang E; Wang X
BMC Cancer; 2021 Feb; 21(1):123. PubMed ID: 33546642
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
Front Oncol; 2021; 11():683502. PubMed ID: 34692475
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Zhu J; Song C; Zheng Z; Xia L; Chen Y; Ke G; Wu X
Front Oncol; 2021; 11():720343. PubMed ID: 34796105
[TBL] [Abstract][Full Text] [Related]
9. Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma.
Chen ATC; Serante AR; Ayres AS; Tonaki JO; Moreno RA; Shih H; Gattás GS; Lopez RVM; Dos Santos de Jesus GR; de Carvalho IT; Marotta RC; Marta GN; Feher O; Neto HS; Ribeiro ISN; Vasconcelos KGMDC; Figueiredo EG; Weltman E
Int J Radiat Oncol Biol Phys; 2024 Jan; ():. PubMed ID: 38232937
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.
Shen F; Li J; Liu F; Sun N; Qiu X; Ding W; Sun X
Front Oncol; 2023; 13():1095362. PubMed ID: 36874124
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Ma J; Song Y; Shou J; Bai Y; Li H; Xie X; Luo H; Ren X; Liu J; Ye D; Bai X; Fu C; Qin S; Wang J; Zhou AP
Front Oncol; 2020; 10():664. PubMed ID: 32457838
[No Abstract] [Full Text] [Related]
16. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of anlotinib treatment for advanced lung cancer.
Shao L; Wang W; Song Z; Zhang Y
Onco Targets Ther; 2019; 12():6549-6554. PubMed ID: 31616163
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.
Hu N; Si Y; Yue J; Sun T; Wang X; Jia Z; Gao S; Li Q; Shao Y; Wang J; Luo Y; Ma F; Xu B; Yuan P
Cancer Biol Med; 2021 Mar; 18(3):849-59. PubMed ID: 33710812
[TBL] [Abstract][Full Text] [Related]
19. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
